

## **NIHR**

### **A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults**

In adults, psychological interventions, clomipramine, SSRIs or combinations of these are all effective, whereas in children and adolescents, psychological interventions, either as monotherapy or combined with specific SSRIs, were more likely to be effective.

Health Technology Appraisal

Systematic search: Yes

June 2016

<http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-43#abstract>

### **Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data**

Oseltamivir and zanamivir cause small reductions in the time to first alleviation of influenza symptoms in adults. The use of oseltamivir increases the risk of nausea, vomiting, psychiatric events in adults and vomiting in children. Oseltamivir has no protective effect on mortality among patients with 2009A/H1N1 influenza.

Prophylaxis with either NI may reduce symptomatic influenza in individuals and in households. The balance between benefits and harms should be considered when making decisions about use of NIs for either prophylaxis or treatment of influenza.

Health Technology Appraisal

Systematic search: Yes

June 2016

<http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-42#abstract>

## **KINGS FUND**

Nil

## **HIS**

### **Comment on: NICE STA392: Adalimumab for treating moderate to severe hidradenitis suppurativa**

Adalimumab (Humira®) is accepted for use within NHS Scotland for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.

SMC Advice

Systematic search: No

June 2016

[http://www.healthcareimprovementscotland.org/our\\_work/technologies\\_and\\_medicines/stas/appraisal\\_392.aspx](http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/stas/appraisal_392.aspx)

**Comment on: NICE STA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia**

Evolocumab (Repatha®) is not recommended for use within NHS Scotland for adults with primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia and non-familial) or mixed dyslipidaemia, as an adjunct to diet.

SMC Advice

Systematic search: No

June 2016

[http://www.healthcareimprovementscotland.org/our\\_work/technologies\\_and\\_medicines/stas/appraisal\\_394.aspx](http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/stas/appraisal_394.aspx)

**Comment on: NICE STA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer**

Ceritinib (Zykadia®) is accepted for use within NHS Scotland for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

SMC Advice

Systematic search: No

June 2016

[http://www.healthcareimprovementscotland.org/our\\_work/technologies\\_and\\_medicines/stas/appraisal\\_395.aspx](http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/stas/appraisal_395.aspx)

**Comment on: NICE STA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus**

Belimumab (Benlysta®) is not recommended for use within NHS Scotland as an add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g. positive anti-dsDNA and low complement) despite standard therapy.

SMC Advice

Systematic search: No

June 2016

[http://www.healthcareimprovementscotland.org/our\\_work/technologies\\_and\\_medicines/stas/appraisal\\_397.aspx](http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/stas/appraisal_397.aspx)

**SGHD**

Nil

**SIGN**

Nil

**HEALTH SCOTLAND**

Nil

## NICE

### **TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa**

Adalimumab is recommended as an option for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

NICE Guidance

Systematic search: Yes

June 2016

<https://www.nice.org.uk/guidance/ta392>

### **TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia**

Alirocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia only if low-density lipoprotein concentrations are persistently above the thresholds specified in the guidance despite maximal tolerated lipid-lowering therapy.

NICE Guidance

Systematic search: Yes

June 2016

<https://www.nice.org.uk/guidance/ta393>

### **TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia**

Evolocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if the dosage is 140 mg every 2 weeks and low-density lipoprotein concentrations are persistently above the thresholds specified in the guidance despite maximal tolerated lipid-lowering therapy.

NICE Guidance

Systematic search: Yes

June 2016

<https://www.nice.org.uk/guidance/ta394>

### **TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer**

Ceritinib is recommended as an option for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have previously had crizotinib.

NICE Guidance

Systematic search: Yes

June 2016

<https://www.nice.org.uk/guidance/ta395>

### **TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma**

Trametinib in combination with dabrafenib is recommended as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

NICE Guidance

Systematic search: Yes

June 2016

<https://www.nice.org.uk/guidance/ta396>

**TA397 Belimumab for treating active autoantibody-positive systemic lupus erythematosus**

Belimumab is recommended as an option as add-on treatment for active autoantibody-positive systemic lupus erythematosus in adults only if there is evidence for serological disease activity, a SELENA-SLEDAI score of greater than or equal to 10 despite standard treatment, and treatment with belimumab is continued beyond 24 weeks only if the SELENA-SLEDAI score has improved by 4 points or more.

NICE Guidance

Systematic search: Yes

June 2016

<https://www.nice.org.uk/guidance/ta397>

**MTG29 GreenLight XPS for treating benign prostatic hyperplasia**

The case for adopting GreenLight XPS for treating benign prostatic hyperplasia is supported in non-high-risk patients. GreenLight XPS is at least as effective in these patients as transurethral resection of the prostate (TURP), but can more often be done as a day-case procedure, following appropriate service redesign. There is currently insufficient high-quality, comparative evidence to support the routine adoption of GreenLight XPS in high-risk patients.

NICE Medical Technology Guidance

Systematic search: Yes

June 2016

<https://www.nice.org.uk/guidance/mtg29>

**EPPI Centre**

Nil

**AHRQ (Agency for Healthcare Research and Quality - USA)**

Nil

**Health Foundation**

Nil

**Canadian Agency for Drugs and Technologies in Health (CADTH)**

**Self-Collected versus Clinician Collected Samples for Sexually Transmitted Infection Testing in Women: A Review of Comparative Clinical Effectiveness Cost-Effectiveness, and Guidelines**

Self-collected samples were commonly associated with high sensitivity and high specificity in comparison with samples collected by clinicians. Study findings also revealed that there was good agreement between the two sampling methods. A home-

based self-sampling strategy may be cost-effective in comparison with standard clinic STI testing and collection of specimens by clinicians.

CADTH Rapid Response Report

Systematic search: Limited

June 2016

<https://www.cadth.ca/self-collected-versus-clinician-collected-samples-sexually-transmitted-infection-testing-women-0>

### **1000 mg versus 650 mg Acetaminophen for Pain or Fever: A Review of the Clinical Efficacy**

Acetaminophen 1000 mg single dose led to a higher percentage of people with at least 50% of pain relief over six hours, and a larger decrease in pain intensity, as compared to acetaminophen 650 mg in various acute post-operative pain conditions, though the evidence was mixed. The risk of adverse events was similar between the two doses, and there were no serious adverse events reported with either dose.

CADTH Rapid Response Report

Systematic search: Limited

June 2016

<https://www.cadth.ca/1000mg-versus-650-mg-acetaminophen-pain-or-fever-review-clinical-efficacy>

### **Frenectomy for the Correction of Ankyloglossia: A Review of Clinical Effectiveness and Guidelines**

Overall, there is evidence that frenectomy is a safe procedure with demonstration of benefit for short-term breastfeeding effectiveness as perceived by the mother. There is less robust evidence regarding objective and long-term measurements of breastfeeding effectiveness, reduction of maternal breast and nipple pain and feeding problems, increased continuation and duration of breastfeeding, and proper growth.

CADTH Rapid Response Report

Systematic search: Limited

June 2016

<https://www.cadth.ca/frenectomy-correction-ankyloglossia-review-clinical-effectiveness-and-guidelines-0>

### **McGill University Health Centre (Canada)**

Nil

### **Health Information & Quality Authority (Ireland)**

Nil

### **Campbell Collaboration**

Nil

## **NICE FORWARD PLANNING – Publications due July 2016**

### **Liver disease (non-alcoholic fatty [NAFLD])**

Clinical Guideline

### **Assessment and Management of Cirrhosis**

Clinical Guideline

### **Leukaemia (acute myeloid, over 30% blasts) – azacitidine**

Single Technology Appraisal

### **Idiopathic pulmonary fibrosis – pirfenidone**

Single Technology Appraisal

### **Asthma (eosinophilic, severe) – mepolizumab**

Single Technology Appraisal

### **Melanoma (metastatic) - talimogene laherparepvec**

Single Technology Appraisal

### **Non-Hodgkin's lymphoma**

Clinical Guideline

### **Oral health for adults in care homes**

Public health guidance

### **Cystic fibrosis (F508del mutation) - lumacaftor (with ivacaftor)**

Single Technology Appraisal

### **Sepsis**

Clinical Guideline